
Kymab hires chief financial officer
pharmafile | February 23, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | anne hyland, kymab
Cambridge-based UK antibody development firm Kymab has appointed Anne Hyland as its chief financial officer.
Hyland takes to the firm over 25 years of financial experience with both public and private companies, and most recently served as the CFO at the BBI Diagnostics Group and Vectura Group.
She also serves as non-executive director and chair of the audit committee at the speciality chemicals company Elementis. Prior to Vectura, Hyland held a number of senior finance position, including director of corporate finance at the-then Celltech Group, Medeva and KPMG.
Dr David Chiswell, chairman and interim chief executive of Kymab, says: “I am very pleased to welcome Anne to Kymab’s senior management team. Anne is an experienced CFO with a successful track record of creating value and growth for both public and private companies. Anne’s strong skill set will be invaluable as we build Kymab into a substantial global biopharmaceutical company.”
Hyland adds: “I am delighted to join Kymab at this exciting time. The significant level of investment the company and management team has attracted is impressive. Kymab is a company with tremendous capabilities and talented people and I look forward to helping build further growth and value.”
Related Content

Sanofi to acquire Kymab for $1.1bn
Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to …

Chinese investors push Kymab backing to $100 million
Kymab, the UK-based antibody biopharmaceutical group, announced that it has secured $100 million in funding. …

Kymab demonstrates promising research for HIV vaccine development
Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the …






